Pharmaceutical Executive’s fifth and final part of its Q&A with Susan Thomas, LucyRx’s chief commercial officer, Thomas points to a gap in GLP-1 coverage for women navigating perimenopause and menopause. The discussion explores how increasing cardiovascular risk during this stage of life can leave some women without affordable treatment options.
She also talks about why targeted benefit design matters. When employers have a clearer picture of risk within their population, they can make more informed coverage decisions and create pathways that improve access to prescription care.
Share